Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures
This study is for adults with advanced or metastatic non-small cell lung cancer (NSCLC) that has specific immune cells called 'tertiary lymphoid structures' within the tumour. Researchers are testing a new treatment combination that targets two specific proteins on cancer cells, PD-L1 and TIGIT. The aim is to see how effective this new approach is in fighting the cancer. Participants may be new to systemic treatment or have had some chemotherapy and immunotherapy before. This is a Phase II study, meaning it's exploring how well the treatment works and its safety, bringing us closer to finding better treatments for lung cancer.
At a glance
What is this study about?
This research study is about finding new and better ways to treat a type of lung cancer called Non-Small Cell Lung Cancer (NSCLC). When cancer is advanced or has spread (metastatic), it can be very challenging to treat. Scientists are always working to understand cancer better and develop new treatments that are more effective and have fewer side effects.
In this study, doctors are focusing on a particular feature found in some lung cancers, which they call 'tertiary lymphoid structures' (TLS). These are like mini-camps of immune cells inside the tumour. They are also looking at two specific proteins on the cancer cells called PD-L1 and TIGIT. These proteins can sometimes help cancer hide from the body's immune system. By targeting these proteins with new medicines, the hope is to unleash the immune system to fight the cancer more effectively.
The main goal of this study is to see how well this new combination treatment works (its 'efficacy') in shrinking tumours or slowing down their growth in patients whose cancer has these specific features. It's a Phase II study, which means it's an important step in testing whether a new treatment is safe and effective enough to be studied in even larger groups of people. This kind of research helps bring us closer to discovering breakthroughs in cancer care.
Key takeaways
- This study is for adults with advanced Non-Small Cell Lung Cancer (NSCLC).
- It's looking at a new combination treatment targeting specific proteins on cancer cells.
- Patients with 'tertiary lymphoid structures' in their tumour are needed.
- You might have had some previous cancer treatment or be new to it.
- This is a Phase II study, exploring how well the treatment works and its safety.
- Careful health checks and specific conditions apply to join.
Who may be eligible?
This study is for adults, aged 18 and over, who have a specific type of lung cancer called Non-Small Cell Lung Cancer (NSCLC). This cancer must be advanced or have spread to other parts of the body, and it must have specific immune cell clusters within the tumour, known as 'tertiary lymphoid structures'.
Participants can be new to treatment for their cancer, or they may have already received some chemotherapy and a type of immunotherapy called a PD1/PDL1 blocker. It's important that they haven't had certain other types of experimental immune treatments before. To join, your body's organs need to be working well, and you should be able to perform daily activities without much difficulty (this is called having a good 'performance status').
For safety reasons, you cannot take part if you have an active or past history of autoimmune diseases (where your immune system attacks your own body), or if you have a weakened immune system. Pregnant or breastfeeding women also cannot participate. There are a few other specific health requirements, which your doctor can explain in more detail.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you an adult aged 18 or older?
- Do you have advanced or metastatic Non-Small Cell Lung Cancer (NSCLC)?
- Has your doctor confirmed that your tumour has 'tertiary lymphoid structures'?
- Do you have good overall health and organ function?
- Are you not currently pregnant or breastfeeding?
- Do you have no history of significant autoimmune disease or a weakened immune system?
What does participation involve?
The detailed information about what taking part involves is not provided in this summary. Generally, in a clinical trial like this, you would have regular hospital visits for check-ups, blood tests, and scans to monitor your health and how the treatment is working. You would receive the investigational medication as prescribed by the study doctors. The duration of treatment and how long you would be followed up after stopping treatment would be clearly explained in the full study information. You would always have the right to withdraw from the study at any time.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is NSCLC?
NSCLC stands for Non-Small Cell Lung Cancer, which is the most common type of lung cancer.
What are 'tertiary lymphoid structures'?
These are small groups of immune cells found inside some tumours, which scientists believe might play a role in how the body responds to cancer.
What does 'advanced or metastatic' mean?
It means the cancer has grown beyond its original location or has spread to other parts of the body.
Will I get a placebo (dummy treatment)?
This information is not provided in the summary, but it's a good question to ask the study team.
Can I continue my usual medications while on the study?
This will depend on the specific medications and will be discussed with the study doctors to ensure safety.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.